Compare CarMax, Inc (KMX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Twist Bioscience Corp — how do they compare? CarMax, Inc trades at $58.02 (market cap $8.26B), while Twist Bioscience Corp trades at $123.23 (market cap $7.72B). The key difference: CarMax, Inc and Twist Bioscience Corp are close in size by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals.
| KMX | TWST | |
|---|---|---|
Market Cap | $8.26B | $7.72B |
Sector | Consumer Cyclical | Health |
52-Week High | $62.17 | $124.88 |
52-Week Low | $30.88 | $24.16 |
Enterprise Value | $26.77B | $7.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $58.78, up 1.03% today, with a bullish technical signal and strong analyst support. Recent earnings have beaten expectations, with Q3 2025 and Q1 2026 EPS surpassing estimates, though Q2 2025 missed. Revenue remains stable around $26.4 billion, but net income margin is thin at 0.84%. The stock is near its consensus price target of $53.09, with a high target of $66.00. Positive news includes a Zacks Strong Buy rating and partnerships to enhance customer experience.
The outlook for KMX is cautiously optimistic, driven by earnings beats and bullish technicals, but high debt and margin pressures pose risks. Investment opportunity lies in continued execution and market share gains, while risks include competitive pressures and economic sensitivity. Analyst consensus leans Hold, with 68.58% holding, suggesting a wait-and-see approach for further growth confirmation.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
